No significant between-group differences were observed in liver enzymes, lipid profile, fasting glucose, HOMA-IR, or inflammatory markers (all <i>p</i> > 0.05).<h4>Conclusion</h4>KD significantly reduced hepatic steatosis and fasting insulin versus CRD, with comparable weight loss but greater muscle loss warranting caution. The gene discussed is INS; the disease is Hepatic steatosis.